metastatic/adv melanoma (mML) | |||
mML - NA - all population | mML - L1 - all population | mML - L2 - all population | |
anti-CTLA-4 | |||
ipilimumab based treatment | |||
ipilimumab alone | MDX010 Ipi vs gp100 | ||
Ipilimumab (10 mg/kg) | EORTC 18071 | Ascierto ... | |
ipilimumab plus gp100 | MDX010 Ipi plus gp100 vs gp100 MDX010 Ipi plus gp100 vs Ipi ... | ||
ipilimumab plus SoC | CA184-024 | ||
tremelimumab | A3671009 |